CYCLACEL PHARMACEUTICALS's gross profit margin for the first quarter of its fiscal year 2015 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. CYCLACEL PHARMACEUTICALS is extremely liquid. Currently, the Quick Ratio is 4.16 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 8.22% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY15||Q1 FY14|
|Net Sales ($mil)||0.51||0.4|
|Net Income ($mil)||-4.91||-4.87|
|Balance Sheet||Q1 FY15||Q1 FY14|
|Cash & Equiv. ($mil)||29.36||28.15|
|Total Assets ($mil)||35.36||33.79|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q1 FY15||Q1 FY14|
|Gross Profit Margin||-1024.61||-1360.35|
|Return on Assets||-54.95||-35.34|
|Return on Equity||-72.66||-51.55|
|Debt||Q1 FY15||Q1 FY14|
|Share Data||Q1 FY15||Q1 FY14|
|Shares outstanding (mil)||34.39||19.82|
|Div / share||0.0||0.0|
|Book value / share||0.79||1.26|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||222670.0||1164662.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 0.83 indicates a significant discount versus the S&P 500 average of 2.83 and a significant discount versus the industry average of 11.49. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, CYCLACEL PHARMACEUTICALS proves to trade at a discount to investment alternatives within the industry.
|CYCC NM||Peers 57.76||CYCC NM||Peers 89.12|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CYCC's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CYCC's P/CF is negative making the measure meaningless.
|CYCC NA||Peers 23.61||CYCC NA||Peers 0.66|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CYCC 0.83||Peers 11.49||CYCC -27.27||Peers -9.87|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CYCC is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, CYCC is expected to significantly trail its peers on the basis of its earnings growth rate.
|CYCC 12.08||Peers 402.26||CYCC 45.89||Peers 342.74|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CYCC is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
CYCC significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV